158 related articles for article (PubMed ID: 22692862)
21. [Assessment of an active pharmacovigilance system carried out by a pharmacist].
Sánchez I; Amador C; Plaza JC; Correa G; Amador R
Rev Med Chil; 2014 Aug; 142(8):998-1005. PubMed ID: 25424672
[TBL] [Abstract][Full Text] [Related]
22. Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital.
Lugardon S; Desboeuf K; Fernet P; Montastruc JL; Lapeyre-Mestre M
Br J Clin Pharmacol; 2006 Aug; 62(2):225-31. PubMed ID: 16842398
[TBL] [Abstract][Full Text] [Related]
23. Adverse drug reactions to anthelmintics.
Bagheri H; Simiand E; Montastruc JL; Magnaval JF
Ann Pharmacother; 2004 Mar; 38(3):383-8. PubMed ID: 14749518
[TBL] [Abstract][Full Text] [Related]
24. Severe injection site reactions after subcutaneous administration of Sayana©.
Jödicke AM; Dahmke H; Damke B; Schäublin M; Kullak-Ublick GA; Weiler S
Swiss Med Wkly; 2017; 147():w14432. PubMed ID: 28634970
[TBL] [Abstract][Full Text] [Related]
25. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
Olivier P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
[TBL] [Abstract][Full Text] [Related]
26. On the clinical evidence leading to tetrazepam withdrawal.
Proy-Vega B; Aguirre C; de Groot P; Solís-García del Pozo J; Jordán J
Expert Opin Drug Saf; 2014 Jun; 13(6):705-12. PubMed ID: 24845943
[TBL] [Abstract][Full Text] [Related]
27. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
28. [Post-marketing safety profile of avocado-soybean unsaponifiables].
Olivier P; Montastruc JL;
Presse Med; 2010 Oct; 39(10):e211-6. PubMed ID: 20937576
[TBL] [Abstract][Full Text] [Related]
29. Adverse drug reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase.
Berhe DF; Juhlin K; Star K; Beyene KG; Dheda M; Haaijer-Ruskamp FM; Taxis K; Mol PG
Trop Med Int Health; 2015 Jun; 20(6):797-806. PubMed ID: 25704305
[TBL] [Abstract][Full Text] [Related]
30. Use and Safety of Anthroposophic Medicinal Products: An Analysis of 44,662 Patients from the EvaMed Pharmacovigilance Network.
Hamre HJ; Glockmann A; Heckenbach K; Matthes H
Drugs Real World Outcomes; 2017 Dec; 4(4):199-213. PubMed ID: 28965336
[TBL] [Abstract][Full Text] [Related]
31. Does memantine induce bradycardia? A study in the French PharmacoVigilance Database.
Gallini A; Sommet A; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2008 Sep; 17(9):877-81. PubMed ID: 18500725
[TBL] [Abstract][Full Text] [Related]
32. Subjective Reasons for Non-Reporting of Adverse Drug Reactions in a Sample of Physicians in Outpatient Care.
Gahr M; Eller J; Connemann BJ; Schönfeldt-Lecuona C
Pharmacopsychiatry; 2016 Mar; 49(2):57-61. PubMed ID: 26744100
[TBL] [Abstract][Full Text] [Related]
33. [Use of the capture-recapture method to assess the frequency of "serious" adverse drug reactions: experience of Toulouse University Hospital].
Montastruc JL; Lugardon S; Desboeuf K; Fernet P; Lapeyre-Mestre M
Bull Acad Natl Med; 2008 Feb; 192(2):421-30; discussion 430-1. PubMed ID: 18819693
[TBL] [Abstract][Full Text] [Related]
34. Remedies containing Asteraceae extracts: a prospective observational study of prescribing patterns and adverse drug reactions in German primary care.
Jeschke E; Ostermann T; Lüke C; Tabali M; Kröz M; Bockelbrink A; Witt CM; Willich SN; Matthes H
Drug Saf; 2009; 32(8):691-706. PubMed ID: 19591533
[TBL] [Abstract][Full Text] [Related]
35. Serious adverse drug reactions in older adults notified to pharmacovigilance.
Charfi R; El Aïdli S; Zaïem A; Kastalli S; Sraïri S; Daghfous R; Lakhal M
Therapie; 2012; 67(5):465-70. PubMed ID: 23241256
[TBL] [Abstract][Full Text] [Related]
36. Pharmacovigilance in oncology: evaluation of current practice and future perspectives.
Baldo P; De Paoli P
J Eval Clin Pract; 2014 Oct; 20(5):559-69. PubMed ID: 24909067
[TBL] [Abstract][Full Text] [Related]
37. Drugs and cancer: an analysis of the French Pharmacovigilance Database.
Durrieu G; Mazau B; Jégu J; Lapeyre-Mestre M; Delord JP; Montastruc JL;
Therapie; 2013; 68(3):149-54. PubMed ID: 23886459
[TBL] [Abstract][Full Text] [Related]
38. Suspected adverse reactions to contrast media in Campania Region (Italy): results from 14 years of post-marketing surveillance.
Sessa M; Rossi C; Mascolo A; Grassi E; Fiorentino S; Scavone C; Reginelli A; Rotondo A; Sportiello L
Expert Opin Drug Saf; 2015; 14(9):1341-51. PubMed ID: 26156557
[TBL] [Abstract][Full Text] [Related]
39. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?
Paludetto MN; Olivier-Abbal P; Montastruc JL
Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1289-94. PubMed ID: 22961933
[TBL] [Abstract][Full Text] [Related]
40. [Analysis of drug safety information using large-scale adverse drug reactions database].
Morikawa K
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2011; (129):1-26. PubMed ID: 22259840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
